Anti-SARS-CoV-2 Drug Development
COVID-19 is a life-threatening infectious disease caused by SARS-CoV-2, which severely affects the human respiratory system. As the number of confirmed COVID-19 cases continues to soar, scientists are working tirelessly to find suitable treatment strategies during this pandemic. Demand for discovering safe and effective drugs has never been this urgent.
As a leading company in the life science research, Creative Bioarray continuously develops resources to support COVID-19 studies. We can help you against COVID-19 and take your drug discovery to the next level. Our researchers are dedicated to helping you find the effective treatment of this unprecedented pandemic. With extensive experience in drug development research, our services would certainly provide valuable information for scientists involved in developing anti-coronavirus drugs.
Our cell-based drug development services are rapid and cost-efficient for preclinical research, covering drug screening, toxicology, safety, efficacy and mechanism of drug action, etc. Services including but not limited to:
One of the promising treatments for COVID-19 is employing antiviral antibodies. Antibodies can inhibit viral replication through a process known as neutralization. Antibodies neutralize viruses in multiple ways, such as blocking the binding of viral proteins to receptors, interfering with cellular uptake, inhibiting viral genome release, etc.
Creative Bioarray can assist you in neutralization assays to determine whether your test substances can neutralize and disrupt SAS-CoV-2. We utilize pseudoviruses or replicating SARS-CoV-2 to infect human ACE2 stable cell lines and subsequently investigate the neutralizing ability of your compounds against SARS-CoV-2. The impact of test substances is based on measuring the inhibitory effects of viral infectivity and the cytopathic effects.
- Cytokine storm studies
Immunomodulatory therapeutics (e.g., NAb) may improve treatment outcomes but also have the potentials of initiating cytokine storm and exacerbate pathological damage in hosts. Studies focus on cytokine storm play a critical role in the prediction of drug effects and disease progression. Creative Bioarray provides cytokine storm monitoring and analysis for your antiviral drug development.
- Inhibition of membrane fusion studies
SARS-CoV-2 is a membrane-enveloped virus that can induce cell-cell fusion and form multinucleated cells, thereby enhancing the rapid spread of viral infection. We are capable of assessing whether your drugs can inhibit cell-cell membrane fusion and hinder syncytium formation.
- Toxicology studies
During COVID-19 drug development, adverse effects of drug candidates also need to be evaluated with caution to prevent drug failure. Our scientific teams can help you in the studies of general toxicity, organ-specific toxicity, and mechanistic toxicity.
- PK/PD studies
Acknowledge of PK/PD relationship is helpful for effectively developing antiviral therapies. PK/PD studies implemented in early drug development allow more successful translation into clinical results.
- Safety pharmacology studies
Creative Bioarray is capable of performing safety pharmacology studies to study the action of drugs and their therapeutic effects, as well as prevent life-threatening conditions. Our services for safety pharmacology, including core battery tests and supplemental studies.
- Drug target validation
Many existing drugs have already been put into clinical use for the treatment of COVID-19. However, it is still unclear how they control viral infections. Identification of drug targets provides valuable information for the development of novel therapeutics and vaccines. Here in Creative Bioarray, we can help you validate the targets of your drug molecules.
We are capable of performing drug testing studies to assist you in screening antiviral drugs as well as evaluating their therapeutic effects and safety issues. A full range of antiviral drugs can be investigated in Creative Bioarray, including but not limited to:
- Neutralizing antibodies
- Antiviral peptides
- mRNA-based therapeutics
- Protease inhibitors
- Nucleotide and nucleoside analogue inhibitors
- Broad-spectrum antiviral drugs
- Existing antiviral drugs
- Anti-inflammatory drugs
Our advanced high throughput screening and high content imaging system enable us to efficiently perform preclinical research for your test drugs, saving your precious time and resources. With years of experience in drug discovery research, our scientific teams are committed to providing you the best and the most qualified services to accelerate the drug development process. Creative Bioarray is always here with you and will do our best to help you overcome the COVID-19 pandemic.
We'd love to hear from you
Please do not hesitate to contact us if you are interested in the anti-SARS-CoV-2 drug development services and would like to know more information. We look forward to working with you and will make every effort to help you combat COVID-19 and save lives.
References
- Abd El-Aziz TM, et al. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status. Infection, Genetics and Evolution. 2020 Apr 19:104327.
- Lip KM, et al. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. Journal of virology. 2006 Jan 15;80(2):941-50.
- Rizzo, P, et al. COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm? Basic Research in Cardiology, 2020; 115(3).
- Zhou G, et al. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020 Mar 15;16(10):1718-1723.
